about
Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomasRole of CHD5 in human cancers: 10 years laterChd5 requires PHD-mediated histone 3 binding for tumor suppressionResearch progress of neuroblastoma related gene variations.Differential expression and sex chromosome association of CHD3/4 and CHD5 during spermatogenesisArchitects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromesTherapeutic targets for neuroblastomas.The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma.Epigenetic dysregulation in laryngeal squamous cell carcinoma.The chromatin remodeler chd5 is necessary for proper head development during embryogenesis of Danio rerio.Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancerRole of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progressionDecreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation.Silencing of CHD5 gene by promoter methylation in leukemia.Apoptotic cell death in neuroblastoma.The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer.Children's Oncology Group's 2013 blueprint for research: neuroblastoma.The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.The roles and regulation of Polycomb complexes in neural development.Mutational dynamics between primary and relapse neuroblastomas.The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain.p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma.CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
P2860
Q26751724-05C6E29A-F193-4601-8776-31ECC06D3DFEQ27006929-3262951D-9882-4086-AEF3-64B8B64BE4E0Q28593132-C75F79B5-70DA-4264-8F5B-C4842FAF4CE0Q33566987-90C9C76F-2C0E-47A5-9475-3D39846CF0F2Q33646049-957E7EB2-82A6-4F7D-B819-69F9F987CD4BQ34520690-E13E8BC6-6468-466F-BDEC-F2DB2F891836Q34560877-56B55402-A9F2-44AD-A78B-5A3F82F90BBEQ35806478-B49105CC-15AD-4F31-9821-FB9F23E6CF87Q35923727-694CE683-3E1B-46E2-A7D0-E997CBB7DDD5Q35974482-CC863153-78A6-4584-9C87-CB2047C4A0FFQ35982052-158321F2-961E-45E7-8446-02AE7CC80BC8Q36245354-5C5A3810-948B-4E74-A7A2-F7572ED3E53CQ37085930-0D517E48-63EE-4EDD-A838-7193E6BDD2B1Q37225412-CBE59933-A0CB-4A5E-9AC8-6DE6A53A5194Q37407277-2E01773D-9364-4E79-87F7-2B328DDA6839Q37472949-35D1962B-8CD9-4ABB-893A-0EB9AE018453Q37679253-42EFBC3B-09C1-4743-BF66-AF63C28BA1EBQ37735355-3FDA0F65-A18B-44F3-A85F-4E23B3BC37F9Q38068818-C46E1F98-2FBA-454E-97F7-EAFB03D36330Q38070334-01F89FFE-EB79-4DE1-82F1-EBEEC42BB7EEQ38264796-487F8008-D618-4488-B674-D8B3FA0BF903Q38859077-25221C92-70BB-4101-A3A9-D1AD107745F7Q41786481-C0A03B0C-9B97-4C41-8FD8-BA45CD0198AFQ42362115-712E84D3-B90F-4CCE-86F8-31FC6E32CC33Q43989091-86A56DB2-B9E7-4786-AB1A-9DB05188E44BQ45921428-B51B715D-EB02-4661-8042-4F1E1593BC8EQ55057685-570CE125-508C-424A-81F4-8A69EC5E20DA
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Mechanisms of CHD5 Inactivation in neuroblastomas.
@ast
Mechanisms of CHD5 Inactivation in neuroblastomas.
@en
type
label
Mechanisms of CHD5 Inactivation in neuroblastomas.
@ast
Mechanisms of CHD5 Inactivation in neuroblastomas.
@en
prefLabel
Mechanisms of CHD5 Inactivation in neuroblastomas.
@ast
Mechanisms of CHD5 Inactivation in neuroblastomas.
@en
P2093
P2860
P1476
Mechanisms of CHD5 Inactivation in neuroblastomas.
@en
P2093
Garrett M Brodeur
Hiroshi Koyama
Jennifer E Light
Mayumi Higashi
Patrick W McGrady
Tiangang Zhuang
Venkatadri Kolla
Wendy B London
P2860
P304
P356
10.1158/1078-0432.CCR-11-2644
P407
P577
2012-01-31T00:00:00Z